The U.S. Food and Drug Administration has signaled a shift in how it will handle compounded peptides, loosening enforcement of some prior restrictions even as safety concerns persist. The move opens a wider channel for customized peptide therapies from compounding pharmacies, while sparking debate among clinicians, patient advocates, and public …